JP Morgan Chase
ALLO icon

JP Morgan Chase’s Allogene Therapeutics ALLO Stock Holding History

JP Morgan Chase’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-27,500
Closed -$1.18M – 5454
2020
Q2 		$1.18M Buy
27,500
+24,600
+848% +$890K ﹤0.01% 3418
2020
Q1 		$56K Hold
2,900
– – ﹤0.01% 4691
2019
Q4 		$75K Buy
+2,900
New +$79.9K ﹤0.01% 4992
2019
Q3 		– Sell
-30,000
Closed -$799K – 5695
2019
Q2 		$799K Buy
30,000
+29,500
+5,900% +$822K ﹤0.01% 3989
2019
Q1 		$14K Buy
+500
New +$14.5K ﹤0.01% 5473

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

JP Morgan Chase's ALLO Position: Q2 2026 in Review

JP Morgan Chase increased its Allogene Therapeutics (ALLO) stake by 0.26% in Q2 2026, buying an estimated $8.32K and bringing the position to 1,438,434 shares worth $3.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3839.

JP Morgan Chase first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $85.4M in Q3 2021. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • JP Morgan Chase held 1,438,434 shares of Allogene Therapeutics worth $3.19M as of Q2 2026.
  • JP Morgan Chase bought 3,787 Allogene Therapeutics shares in Q2 2026, an estimated $8.32K.
  • Allogene Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3839 holding.
  • JP Morgan Chase first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • JP Morgan Chase's Allogene Therapeutics position peaked at $85.4M in Q3 2021.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.